January 1, 1994Thrombosis and Haemostasis

Pharmacological Properties of CY 216 and of Its ACLM and BCLM Components in the Rabbit

View Full Paper

Ask AI

Bookmark

Population

Rabbit models (Wessler model for venous thrombosis and rabbit ear model for hemorrhage)

Comparison

CY 216 and its components ACLM and BCLM… vs Unfractionated heparin and comparison between…

Design

Preclinical

Authors

VPV. PeyrouInstitut Alfred Fournier JLJ C LormeauSanofi (France)CCC. CaranobeCentre Hospitalier Universitaire de Toulouse

Discussion

Member takes

Implication

Preclinical data support LMWHs over UFH for lower bleeding risk; leaves open translation to human venous thrombosis therapy.

Structured PICO

Population

Rabbit models (Wessler model for venous thrombosis and rabbit ear model for hemorrhage)

Intervention

CY 216 and its components ACLM (>5.4 kDa) and BCLM (<5.4 kDa) administered via bolus IV, continuous infusion, or subcutaneous injection

Comparator

Unfractionated heparin (in hemorrhage model) and comparison between the components

Outcome

Antithrombotic effect (inhibition of venous thrombosis growth) and pro-haemorrhagic propertiessurrogate

The anti-factor Xa activity of low molecular weight heparin largely contributes to its antithrombotic effect, while its lower haemorrhagic potential compared to unfractionated heparin is related to molecular weight rather than anti-thrombin activity.

Cite This Study

Peyrou et al. (1994) studied this question.

synapsesocial.com/papers/6a728e6dfebe604dd70aaa8b https://doi.org/10.1055/s-0038-1648851

View Full Paper

Ask AI

Bookmark

Pharmacological Properties of CY 216 and of Its ACLM and BCLM Components in the Rabbit

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Pharmacological Properties of CY 216 and of Its ACLM and BCLM Components in the Rabbit

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider